심 재 준심 재 준 Am J Gastroenterol 2007;102:2448-2457.

Slides:



Advertisements
Similar presentations
Intermediate stage HCC management
Advertisements

Staging Strategy and Treatment for Patients With HCC
Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine.
The effect of improved HCV diagnosis and treatment on public health The effect of improved HCV diagnosis and treatment on public health P Mathurin Hôpital.
Interventional Oncology Michael Kotton MD October 27, 2012.
Protein GP73 (GOLGI PROTEIN 73) A NEW NON-INVASIVE BIOMARKER FOR ASSESSING LIVER FIBROSIS AND RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA N.K. Gatselis,
Am J Gastroenterol 2012; 107:46–52. Drmohammad Sadrkabir.
V.E.I.L. Liver Cancer Prevention. 1. Vaccination Birth dose + 2 Universal for those not already chronics Screening pregnant women Catch up vaccination.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
As noted by Gary H. Lyman (JCO, 2012) “CER is an important framework for systematically identifying and summarizing the totality of evidence on the effectiveness,
HCC Guidelines and recommendation Typical feature (wash in/wash out) New mass/nodule NoYes Alternative imaging technique Atypical featureTypical.
Cholestatic liver diseases:
HEPATOCELLULAR CARCINOMA Monton. HCC in Thailand Most common cancer in Thai male Incidence 5 x 100,000 / year Male : female = 3-8:1 Age > 40 yr.
EPIB-591 Screening Jean-François Boivin 29 September
4 YEARS SURVIVAL OF 100 HCC PATIENTS TREATED WITH DC BEAD: A RETROSPECTIVE ANALYSIS Marta Burrel Vascular Interventional Unit Barcelona Clinic Liver Cancer.
Surveillance for HCC. Surveillance in cancer Definition: Repeated application of a test over time with the aim of reducing disease-specific mortality.
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
FT in prognostic of HBV FibroTest: predictive value in HBV.
Patient Information - Viral Hepatitis B (HBV)
Multicenter Study of Down-staging of Hepatocellular Carcinoma (HCC) to within Milan Criteria before Liver Transplantation Neil Mehta, MD; Jennifer Guy,
HCC Guidelines
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Evaluating Screening Programs Dr. Jørn Olsen Epi 200B January 19, 2010.
Prognosis study EBM questions. Prognostic factors Characteristics of patient that may predict eventual outcome Several types: demographic (eg age) disease-specific.
Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.
HCC Guidelines and recommendation Diagnostic algorithm and recall policy.*One imaging technique only recommended in centers of excellence with high-end.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
A2ALL When Using A2ALL Slides We welcome the use of A2ALL slides, as we value the distribution of our research for the benefit of patient care and transplant.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Date of download: 5/31/2016 From: Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years: A Comparative Modeling.
Hamid Tavakkoli, MD Associate Prof. of Gastroenterology.
CLINICAL OUTCOME OF 251 PATIENTS WITH EXTRAHEPATIC METASTASIS AT INITIAL DIAGNOSIS OF HEPATOCELLULAR CARCINOMA: DOES TRANSARTERIAL CHEMOEMBOLIZATION IMPROVE.
Treatment Strategy for Recurrent Hepatocellular Carcinoma: Salvage Transplantation, Repeated Resection, or Radiofrequency Ablation? Albert C. Y. Chan,
Thomas Sersté1,2, Vincent Barrau3, Violaine Ozenne1, Marie Pierre Vullierme3, Pierre Bedossa5,6, Olivier Farges4, Dominique-Charles Valla1,6, Valérie Vilgrain3,6,
Management of Hepatocellular carcinoma
1 Yize R. Wang, MD, PhD, John R. Cangemi, MD, Edward V. Loftus Jr, MD and Michael F. Picco, MD, PhD Am J Gastroenterol 2013;108:444–449 F1 김혁 / Prof. 김효종.
GASTROENTEROLOGY 2010;138:493–502 심 재 준 월요 저널.
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Acute Renal Failure in Aneurysmal Subarachnoid Hemorrhage: Nationwide Analysis of Hospitalizations in the United States Kavelin Rumalla 1, Adithi Y. Reddy.
F. 정 회 훈 Am J Gastroenterol 2012;107:46-52 Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy:
Golgi Protein-73 Shows Promise as a Sensitive Serum Marker for HCC Slideset on: Marrero J, Romano P, Nikolaeva O, et al. GP73, a resident golgi glycoprotein,
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
HEPATOLOGY, Vol. 61, No. 6, Introduction At least 1 / 3 of liver cirrhosis (LC) Chronic hepatitis B (CHB) Significant proportion of CHB progress.
TACE for HCC in a regional centre: 5 year audit and assessment of baseline predictors of outcome Iain DS Morrison, #R Kasthuri, EH Forrest, S Barclay,
Dr. Mohammed Omar Khalifa
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Figure #1 Overall survival Figure #2 Disease free survival
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
Clinical outcome after SVR: Veterans Affairs
Presented By: Sally Saad Mandour Esawy
A Review of the Critical Role of Imaging in Primary Liver Malignancy
Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
HEPATOCELLULAR CARCINOMA (HCC) at
Marcus-Alexander Wörns, Peter Robert Galle  Journal of Hepatology 
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Impact of metabolic risk factors on HCC
Liver cancer: Approaching a personalized care
Epidemiology & First option of treatment
Hepatocellular Carcinoma in Patients with
Josep M. Llovet  Clinical Gastroenterology and Hepatology 
Lance L. Stein, MD, Marty T. Sellers, MD, MPH 
Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis  Karin L. Andersson, Joshua A. Salomon,
Bile duct invasion itself can be the prognosis factor in early HCC
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Prognostic effect of complete pathologic response following TACE on HCC patients undergoing liver resection or transplantation Prognostic effect of complete.
Multidisciplinary team approach to hepatocellular carcinoma management in a liver transplant center from Romania Cerban R.1, Iacob S.1, Croitoru A.1, Popescu.
Presentation transcript:

심 재 준심 재 준 Am J Gastroenterol 2007;102:

Introduction  Hepatocellular carcinoma  Detected at an advanced tumor state  Precluding effective treatment  HCC surveillance in patients at risk  US and or AFP every 6-12mo  Cirrhosis and HCC  HCC underlying cirrhosis ; >80%  European and American guidelines for HCC management  “to those cirrhotics who would be treated if diagnosed with HCC”

Introduction  The Child-Pugh(CP) classification  Severity of cirrhosis and its prognosis  Cost-effective surveillance to which patients?  Child A : effective  Child B : ?  Child C : futile  Yuen MF et al, Hepatology 2000;31:330-5  Class B : prognostic benefit  Trevisani F et al, Am J Gastroenterol 2002;97:734  Class B : borderline significancy  Class B: Surveillance? Gray zone

Introduction  Advances in HCC, LC management  Major advances in HCC management in recent years  More sensitive diagnostic imaging, TACE, optimized the therapeutic strategy  Reduction of cirrhosis-related mortality due to an improved management of its complications  The time has come to re-evaluate surveillance for HCC in intermediate/advanced cirrhosis  Surveillance of class B / class C ?

Aim  Whether surveillance improves the prognosis of patients belonging to classes B and C at the time of HCC diagnosis.

Methods – 1. Patients  Cohort study  The ITA.LI.CA database  1,834 HCC (January 1987 to December 2004 at 10 medical institutions)  Eligible criteria  the interval of surveillance  the C-P class at the time of HCC diagnosis  608 patients: 468 class B and 140 class C cases  Exclusion criteria  class A (1084 patients),  class unreported (59 patients)  surveillance interval unspecified (83 patients)  Patients group  Group 1 : 252 (41.4%), HCC was detected during regular surveillance  every 6 (172 cases [68.3%]) or 12 (80 [31.7%]) months  Group 2 : 356 (58.6%), in whom HCC was detected "incidentally,"  during examination for other diseases (181 patients [50.8%]), or because of symptom appearance (175 patients [49.2%]).

Methods  Etiology and Diagnosis of Cirrhosis  HBV, HCV, Alcoholic, multietiology  Others : cryptogenic, hereditary hemochromatosis, PBC  Diagnosis and Staging of HCC  Histology or cytology ; 42 patients  AFP>200ng/mL, typical imaging features  Unifocal, paucifocal( 3nodules), infiltrating, massive  United Network of Organ Sharing(UNOS) system, CLIP system  Statistical Analysis  to minimize the lead time bias (Schwartz’s formula, Cancer 1961;14: )  The calculated lead time(t) : 238 days(6mo), 121 days(1yr) t = DT x 3 x log(d1/d0)/log(2)

Lead time bias ScreeningSymptoms Death Survival time Survival time with screening Adams PC et al. Hepatology 2004;39:

Length bias Screening test Tumor doubling time Fast growing tumor 1 case detected Slow growing tumor 3 cases detected Adams PC et al. Hepatology 2004;39:

Results : Child-Pugh B patients

Figure 1. Survival of Child-Pugh class B patients according to the modality of cancer diagnosis Group 1 ; 17.1, 95% CI 13.5~20.6 months Group 2 ; 12.0, 95% CI 9.4~14.6 months Group 1: 16.0, 95% CI 12.9~19.0 months, p=0.253, if OLT(-)

Results : Table 3. Variables associated with survival in Child-Pugh B patients

Results :Child-Pugh C patients

Figure 2. Survival of Child-Pugh class C patients according to the modality of cancer diagnosis Group 1 ; 7.1, 95% CI 2.1 ~ 12.1 months Group 2 ; 6.0, 95% CI 4.1~7.9 months

Results : Table 6. Variables associated with survival in Child-Pugh C patients

Discussion  Relation between liver function and outcome of surveillance  Only two, in Hong Kong and Italy  Hong Kong :  Low class B cases  Only compared with symptomatic patients  Length bias, lead time bias ; not adjusted  Italy  Improved HCC, cirrhosis management  Doubled sample size

Discussion  OLT ; liver transplantation  Class B;  crucial to achieve a better survival rate by surveillance  Age, extrahepatic comorbidity, ability of transplantation  Class C;  Patients for OLT : screening is strongly recommended  OLT 불가능한 class C 환자는 ?  HCC vs. cirrhosis-related mortality

Discussion  Limitation  Not randomized trial  Incidental detection by US…  Effect of some biases  Selection bias  Surveyed Class B : younger, HCV, non-alcoholics  Intercenter heterogeneity of HCC Mx  Disease-specific mortality ; not assessed

Conclusions  Class B  간암 조기 발견을 위한 surveillance 는 생존률을 증 가  특히, 간암 발견 당시 간이식이 가능한 환자들을 더 중점으로 해야 하겠다.  Class C  간암 발생 전에 간이식을 고려해야 하겠고 이런 환자 들이 surveillance 의 대상이 되겠다.  그 외 환자들에게는 간암 surveillance 가 의미 없다.